It is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma after other treatments have failed. Further trials are ongoing to confirm benefits as of 2019.
Duvelisib
Glasdegib
Alpelisib
Idelalisib
Etalocib
Sotorasib
Vismodegib
Atosiban